InvestSMART

Microba Life Sciences Limited (ASX: MAP) - Announcements

- Current share price for MAP : $0.055

ASX company news and announcements for Microba Life Sciences Limited (MAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Microba Life Sciences Limited (MAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Microba Life Sciences Limited (MAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Microba Life Sciences Limited (MAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 Change in substantial holding 23 Aug 2022 6:05PM $0.210 $0.055 fallen by 73.81%
$39 Change in substantial holding 19 Aug 2022 3:18PM $0.215 $0.055 fallen by 74.42%
$39 Microba receives two AusIndustry Advanced Overseas Findings 22 Jul 2022 3:56PM $0.295 $0.055 fallen by 81.36%
$39 Investor Update - Q4 FY22 Results 20 Jul 2022 9:25AM $0.240 $0.055 fallen by 77.08%
$39 Q4 FY22 Quarterly Activities Report & Appendix 4C 20 Jul 2022 9:05AM $0.240 $0.055 fallen by 77.08%
$39 Details of Q4 FY22 Investor Webinar 19 Jul 2022 9:05AM $0.220 $0.055 fallen by 75%
$39 Global Leader IFF and Microba Reach First Milestone 4 Jul 2022 9:07AM $0.200 $0.055 fallen by 72.50%
$39 Genova Diagnostics Partnership Commences in the US 30 Jun 2022 9:12AM $0.225 $0.055 fallen by 75.56%
$39 G42 Healthcare Partnership Commences Operation 28 Jun 2022 9:38AM $0.280 $0.055 fallen by 80.36%
$39 Next Generation Product Released to Health Professionals 23 Jun 2022 9:11AM $0.255 $0.055 fallen by 78.43%
$39 Application for quotation of securities - MAP 15 Jun 2022 9:01AM $0.210 $0.055 fallen by 73.81%
$39 Microba & Ginkgo Commence Therapeutics Program 8 Jun 2022 9:08AM $0.265 $0.055 fallen by 79.25%
$39 Release of Restricted Securities from Escrow 6 Jun 2022 6:01PM $0.265 $0.055 fallen by 79.25%
$39 Microba Appoints CRO for IBD Clinical Trial 27 May 2022 9:13AM $0.245 $0.055 fallen by 77.55%
$39 Partnership signed with nib-backed Midnight Health 26 May 2022 9:05AM $0.250 $0.055 fallen by 78%
$39 Change in substantial holding 10 May 2022 12:44PM $0.325 $0.055 fallen by 83.08%
$39 Microba Appoints Senior US Sales Lead 9 May 2022 9:13AM $0.370 $0.055 fallen by 85.14%
$39 Microba Accelerates Cancer Program 5 May 2022 9:50AM $0.375 $0.055 fallen by 85.33%
$39 International Conference Presentation 29 Apr 2022 9:14AM $0.380 $0.055 fallen by 85.53%
$39 Microba CSO presents to US industry conference 13 Apr 2022 1:35PM $0.385 $0.055 fallen by 85.71%
$39 Change of Director's Interest Notice - Prof Ian Frazer 13 Apr 2022 1:09PM $0.370 $0.055 fallen by 85.14%
$39 Change of Director's Interest Notice - Pasquale Rombola 13 Apr 2022 1:07PM $0.370 $0.055 fallen by 85.14%
$39 ShareCafe Small Cap Hidden Gems Presentation 7 Apr 2022 9:28AM $0.375 $0.055 fallen by 85.33%
$39 Becoming a substantial holder 6 Apr 2022 3:48PM $0.380 $0.055 fallen by 85.53%
$39 Microba Appoints New Therapeutics Head 6 Apr 2022 8:44AM $0.350 $0.055 fallen by 84.29%

301 - 325 of 697 results

Page 13 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.